1-Methyl-3-(propane-2-sulphonyl)benzene | 69113-07-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Methyl-3-(propane-2-sulphonyl)benzene
• 英文别名: 1-Methyl-3-propan-2-ylsulfonylbenzene
• CAS: 69113-07-1
• 化学式: C₁₀H₁₄O₂S
• 分子量: 198.286
• InChiKey: XCWCIKYMVDFWLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] MACROCYCLIC BETA-SECRETASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-SECRÉTASE MACROCYCLIQUES
  申请人：SCHERING CORP

  公开号：WO2006014944A1

  公开（公告）日：2006-02-09

  Disclosed are novel compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, n and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula (I) and at least one compound selected from the group consisting of -secretase inhibitors other than those of formula (I), HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.

  揭示了以下式（I）的新化合物：或其药学上可接受的盐或溶剂，其中R1、R2、R3、n和X如规范中所定义。还揭示了包括式（I）化合物的药物组合物。还揭示了治疗认知或神经退行性疾病如阿尔茨海默病的方法。还揭示了治疗认知或神经退行性疾病的方法，包括向需要此类治疗的患者施用至少一种式（I）化合物和选自-分泌酶抑制剂（不包括式（I）的那些）、HMG-CoA还原酶抑制剂、γ-分泌酶抑制剂、非甾体抗炎药、N-甲基-D-天冬氨酸受体拮抗剂、胆碱酯酶抑制剂和抗淀粉样抗体的化合物组合物的方法。
• Diaryl piperidines as CB1 modulators
  申请人：Scott D. Jack

  公开号：US20070203183A1

  公开（公告）日：2007-08-30

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

  具有通式（I）的一种化合物，或其药学上可接受的盐、溶剂合物或酯，可用于治疗代谢综合征（例如肥胖、腰围、脂质谱和胰岛素敏感性）、神经炎症性疾病、认知障碍、精神病、成瘾行为、胃肠道疾病和心血管疾病等疾病、疾病或症状。
• Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
  申请人：Balog Aaron James

  公开号：US20070088029A1

  公开（公告）日：2007-04-19

  Tricycloundecanes compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.

  三环十一烷化合物，以及在治疗核激素受体相关疾病如癌症和免疫紊乱中使用这些化合物的方法，以及含有这些化合物的药物组合物被披露。
• Sulfone derivatives as 5-HT7 receptor ligands
  申请人：——

  公开号：US20040229864A1

  公开（公告）日：2004-11-18

  The present invention relates to sulfone derivatives of formula (I): Ar—SO 2 —CR 2 R 3 -L-N(R 1 ) 2 I wherein Ar, L, R 1 , R 2 and R 3 are as defined herein, and pharmaceutically acceptable salts and N-oxides thereof, useful in the treatment of a condition which is susceptible to treatment by modulation of 5-HT 7 receptor activity, such as depression or a sleep disorder.

  本发明涉及式（I）的砜衍生物：Ar—SO2—CR2R3-L-N(R1)2I，其中Ar，L，R1，R2和R3如本文所定义，并且其药用盐和N-氧化物，用于治疗通过调节5-HT7受体活性可治疗的疾病，如抑郁症或睡眠障碍。
• Substituted pyrazoles as p38 kinase inhibitors
  申请人：Naraian S. Ashok

  公开号：US20070078146A1

  公开（公告）日：2007-04-05

  A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.

  描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA定义，其中R1、R2、R3和R4如规范中所述。